xten peptide protein peptides - A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner proteins Understanding XTEN Peptide Protein: A Revolution in Therapeutic Half-Life Extension

XTENsequence The field of biopharmaceuticals is constantly seeking innovative ways to enhance the efficacy and delivery of therapeutic agentsGenetically Encoded XTEN‐based Hydrogels with Tunable .... One such breakthrough is the development of XTEN peptide protein, a class of unstructured, hydrophilic, biodegradable protein polymers engineered to significantly extend the in vivo half-life of therapeutic peptides and proteins. This technology offers a promising avenue for improving drug delivery, reducing dosing frequency, and ultimately, enhancing patient outcomes.Extension of in vivo half-life of biologically active peptides ...

At its core, XTEN is a genetically encoded polypeptide designed for maximum biocompatibility and minimal immunogenicityAmunix, Inc. And PolyPeptide Laboratories Inc. Enter Into .... Unlike traditional methods like PEGylation, XTEN offers a biological alternative that can be produced entirely in E. coli, streamlining manufacturing processes. The XTEN sequence itself is characterized by its unstructured nature and a specific composition of amino acids, often described as being comprised of 36-residue pseudorepeats of only six amino acids (A, E, G, P, S, and T). This unique composition, which lacks hydrophobic residues typically associated with immunogenicity, contributes to its safe and nonimmunogenic profile across various animal species. Data suggests that XTEN has entered clinical trials, underscoring its therapeutic potentialThe terms "polypeptide", "peptide", and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear ....

The primary mechanism by which XTEN functions is through increasing the hydrodynamic volume of the fused molecule. This "bulking effect," similar to that achieved by PEGylation, reduces renal clearance and limits enzymatic degradation, thereby prolonging the presence of the therapeutic agent in the bloodstream作者：VN Podust·2016·被引用次数：205—XTEN™ is a class ofunstructured hydrophilic, biodegradable protein polymersdesigned to increase the half-lives of therapeutic peptides and .... This is particularly crucial for peptides and proteins that are naturally cleared from the body very rapidly. For instance, molecules like Glucagon-like peptide 2 (GLP2), an intestinal growth factor, can benefit immensely from such half-life extension, potentially leading to improved therapeutic effects in conditions affecting the gut.

Research has demonstrated the versatility of XTEN in extending the in vivo half-life of a wide array of biologically active molecules. Studies have shown successful fusions of XTEN to therapeutic proteins such as exenatide (used in diabetes treatment), human growth hormone, and even imaging probes like annexin A5. The XTENlinker sequence can be precisely engineered, allowing for tunable control over the half-life extension. This means that the XTEN polymer can be tailored to achieve specific pharmacokinetic profiles for different therapeutic applications.

The advantages of XTEN peptide protein extend beyond just half-life extension.作者：A Haeckel·2016·被引用次数：47—The aim of this study was to design a long-circulating, activatable cytostatic drug that is completely producible in E. coli. Its inherent biodegradability ensures that it is naturally broken down and cleared from the body, avoiding the long-term accumulation issues sometimes associated with other technologies. Furthermore, the XTEN protein is characterized by its large hydrodynamic volume and negative charge, contributing to its favorable pharmacokinetic properties. The development of extended recombinant polypeptide (XTEN) compositions and XTEN conjugate compositions signifies the ongoing innovation in this area, offering various ways to leverage the benefits of XTEN作者：S Ding·2014·被引用次数：80—XTENs areunstructured, nonrepetitive protein polymersdesigned to prolong the in vivo half-life of pharmaceuticals by introducing a bulking effect similar ....

The ability to genetically fuse XTEN to a protein drug or other biological entities using recombinant technology is a significant advancement. This approach allows for a seamless integration of the half-life extending moiety, creating a single, unified therapeutic molecule. This is exemplified in the development of multivalent antiviral XTEN–peptide conjugates with long in vivo half-life and enhanced solubility, showcasing the potential for creating more potent and effective antiviral therapies.

In essence, XTEN peptide protein represents a sophisticated platform technology designed to increase the half-lives of therapeutic peptides and proteins作者：VN Podust·2013·被引用次数：56—Abstract.XTEN, unstructured biodegradableproteins, have been used to extend the in vivo half-life of genetically fused therapeuticproteinsandpeptides.. Its unstructured, nonrepetitive protein polymers offer a biological solution that is both effective and well-tolerated.Multivalent Antiviral XTEN–Peptide Conjugates with Long in ... As research continues, the application of XTEN is expected to expand, offering new possibilities for drug development and patient care by ensuring that therapeutics remain active in the body for longer durations, thereby potentially enabling less frequent dosing and improved treatment outcomes.作者：JI Bennett·2024·被引用次数：21—Comprised of 36-residue pseudorepeats of only six amino acids(A, E, G, P, S, and T), XTEN lacks hydrophobic residues typically associated with ... The technology is poised to play a pivotal role in the future of biopharmaceutical development, with its ability to extend the in vivo half-life of therapeutics payloads being a key driver of its adoption.